Antiretroviral therapy can effectively block HIV-1 replication and prevent or reverse
immunodeficiency in HIV-1-infected individuals. However, viral replication resumes within …

Therapeutic strategies are being clinically tested either to eradicate latent HIV reservoirs or
to achieve virologic control in the absence of antiretroviral therapy. Attaining this goal will …

Background Antiretroviral therapy (ART) halts HIV-1 replication, decreasing viremia to below
the detection limit of clinical assays. However, some individuals experience persistent …

The quantitative viral outgrowth assay (QVOA) provides a precise minimal estimate of the
reservoir of resting CD4+ T-cell infection (resting cell infection [RCI]). However, the variability …

The latent reservoir for HIV-1 in resting CD4+ T cells is a major barrier to cure. Several lines
of evidence suggest that the latent reservoir is maintained through cellular proliferation …

Background: It is unknown whether the reduction in HIV-1 reservoirs seen after allogeneic
hematopoietic stem cell transplantation (HSCT) with susceptible donor cells is sufficient to …

HIV-1 reservoirs preclude virus eradication in patients receiving highly active antiretroviral
therapy (HAART). The best characterized reservoir is a small, difficult-to-quantify pool of …

The major obstacle to curing HIV infection is the persistence of cells with intact proviruses
that can produce replication-competent virus. This HIV reservoir is believed to exist primarily …

HIV-1 can establish a state of latent infection at the level of individual T cells. Latently
infected cells are rare in vivo and appear to arise when activated CD4+ T cells, the major …

Latent reservoirs of HIV-1-infected cells are refractory to antiretroviral therapies (ART) and
remain the major barrier to curing HIV-1. Because latently infected cells are long-lived …